综述 |
|
|
|
|
HIV-1广谱中和抗体筛选技术的研究进展* |
蒋雯玲1,邓婷婷2,李少伟1,2,顾颖1,2,**() |
1 厦门大学公共卫生学院 国家传染病诊断试剂与疫苗工程技术研究中心 厦门 361102 2 厦门大学生命科学学院 分子疫苗学与分子诊断学国家重点实验室 厦门 361102 |
|
Research Progress of the Screening Technique for HIV- 1 Broad-spectrum Neutralizing Antibodies |
JIANG Wen-ling1,DENG Ting-ting2,LI Shao-wei1,2,GU Ying1,2,**() |
1 National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen 361102, China 2 State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences, Xiamen University, Xiamen 361102, China |
引用本文:
蒋雯玲, 邓婷婷, 李少伟, 顾颖. HIV-1广谱中和抗体筛选技术的研究进展*[J]. 中国生物工程杂志, 2023, 43(9): 46-54.
JIANG Wen-ling, DENG Ting-ting, LI Shao-wei, GU Ying. Research Progress of the Screening Technique for HIV- 1 Broad-spectrum Neutralizing Antibodies. China Biotechnology, 2023, 43(9): 46-54.
链接本文:
https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.2303035
或
https://manu60.magtech.com.cn/biotech/CN/Y2023/V43/I9/46
|
[1] |
Lee J H, Crotty S. HIV vaccinology: 2021 update. Seminars in Immunology, 2021, 51: 101470.
doi: 10.1016/j.smim.2021.101470
|
[2] |
UNAIDS 2021 Epidemiological Estimates. Global HIV & AIDS statistics. [2022-02-24]. https://www.unaids.org/en/resources/fact-sheet.
|
[3] |
Li G D, Wang Y L, De Clercq E. Approved HIV reverse transcriptase inhibitors in the past decade. Acta Pharmaceutica Sinica B, 2022, 12(4): 1567-1590.
doi: 10.1016/j.apsb.2021.11.009
pmid: 35847492
|
[4] |
Markham A. Ibalizumab: first global approval. Drugs, 2018, 78(7): 781-785.
doi: 10.1007/s40265-018-0907-5
pmid: 29675744
|
[5] |
Mullard A. FDA approves 100th monoclonal antibody product. Nature Reviews Drug Discovery, 2021, 20(7): 491-495.
doi: 10.1038/d41573-021-00079-7
pmid: 33953368
|
[6] |
Corey L, Gilbert P B, Juraska M, et al. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. The New England Journal of Medicine, 2021, 384(11): 1003-1014.
doi: 10.1056/NEJMoa2031738
pmid: 33730454
|
[7] |
Gaebler C, Nogueira L, Stoffel E, et al. Prolonged viral suppression with anti-HIV-1 antibody therapy. Nature, 2022, 606(7913): 368-374.
doi: 10.1038/s41586-022-04597-1
|
[8] |
Gruell H, Gunst J D, Cohen Y Z, et al. Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial. The Lancet Microbe, 2022, 3(3): e203-e214.
doi: 10.1016/S2666-5247(21)00239-1
|
[9] |
Haynes B F, Burton D R, Mascola J R. Multiple roles for HIV broadly neutralizing antibodies. Science Translational Medicine, 2019, 11(516): eaaz2686.
doi: 10.1126/scitranslmed.aaz2686
|
[10] |
Julg B, Barouch D. Broadly neutralizing antibodies for HIV-1 prevention and therapy. Seminars in Immunology, 2021, 51: 101475.
doi: 10.1016/j.smim.2021.101475
|
[11] |
Prashar P, Swain S, Adhikari N, et al. A novel high-throughput single B-cell cloning platform for isolation and characterization of high-affinity and potent SARS-CoV-2 neutralizing antibodies. Antiviral Research, 2022, 203: 105349.
doi: 10.1016/j.antiviral.2022.105349
|
[12] |
Smith S A, Crowe J E Jr. Use of human hybridoma technology to isolate human monoclonal antibodies. Microbiology Spectrum, 2015, 3(1): AID-0027-2014.
|
[13] |
Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 1975, 256(5517): 495-497.
doi: 10.1038/256495a0
|
[14] |
Parray H A, Shukla S, Samal S, et al. Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives. International Immunopharmacology, 2020, 85: 106639.
doi: 10.1016/j.intimp.2020.106639
|
[15] |
Stephenson K E, Wagh K, Korber B, et al. Vaccines and broadly neutralizing antibodies for HIV-1 prevention. Annual Review of Immunology, 2020, 38: 673-703.
doi: 10.1146/annurev-immunol-080219-023629
pmid: 32340576
|
[16] |
Moraes J Z, Hamaguchi B, Braggion C, et al. Hybridoma technology: is it still useful? Current Research in Immunology, 2021, 2: 32-40.
|
[17] |
Mitra S, Tomar P C. Hybridoma technology; advancements, clinical significance, and future aspects. Journal, Genetic Engineering & Biotechnology, 2021, 19(1): 159.
|
[18] |
Lonberg N, Taylor L D, Harding F A, et al. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature, 1994, 368(6474): 856-859.
doi: 10.1038/368856a0
|
[19] |
Markham A. Correction to: Ibalizumab: first global approval. Drugs, 2018, 78(8): 859.
doi: 10.1007/s40265-018-0926-2
pmid: 29846911
|
[20] |
Wang L W, Shen H Y, Nobre L, et al. Epstein-Barr-virus-induced one-carbon metabolism drives B cell transformation. Cell Metabolism, 2019, 30(3): 539-555.e11.
doi: S1550-4131(19)30306-7
pmid: 31257153
|
[21] |
Damania B, Kenney S C, Raab-Traub N. Epstein-Barr virus: biology and clinical disease. Cell, 2022, 185(20): 3652-3670.
doi: 10.1016/j.cell.2022.08.026
pmid: 36113467
|
[22] |
Valgardsdottir R, Cattaneo I, Napolitano G, et al. Identification of human SARS-CoV-2 monoclonal antibodies from convalescent patients using EBV immortalization. Antibodies, 2021, 10(3): 26.
doi: 10.3390/antib10030026
|
[23] |
Sun Z H, Lu S Q, Yang Z, et al. Isolation and characterization of an HIV-1 envelope glycoprotein-specific B-cell from an immortalized human naïve B-cell library. Journal of General Virology, 2017, 98(4): 791-798.
doi: 10.1099/jgv.0.000706
pmid: 28073404
|
[24] |
Miller N L, Clark T, Raman R, et al. Glycans in virus-host interactions: a structural perspective. Frontiers in Molecular Biosciences, 2021, 8: 666756.
doi: 10.3389/fmolb.2021.666756
|
[25] |
Krebs S J, Kwon Y D, Schramm C A, et al. Longitudinal analysis reveals early development of three MPER-directed neutralizing antibody lineages from an HIV-1-infected individual. Immunity, 2019, 50(3): 677-691.e13.
doi: S1074-7613(19)30074-3
pmid: 30876875
|
[26] |
Mahdavi S Z B, Oroojalian F, Eyvazi S, et al. An overview on display systems (phage, bacterial, and yeast display) for production of anticancer antibodies; advantages and disadvantages. International Journal of Biological Macromolecules, 2022, 208: 421-442.
doi: 10.1016/j.ijbiomac.2022.03.113
|
[27] |
Wang Y, Shan Y M, Gao X Y, et al. Screening and expressing HIV-1 specific antibody fragments in Saccharomyces cerevisiae. Molecular Immunology, 2018, 103: 279-285.
doi: 10.1016/j.molimm.2018.10.013
|
[28] |
Mathew E, Zhu H, Connelly S M, et al. Display of the HIV envelope protein at the yeast cell surface for immunogen development. PLoS One, 2018, 13(10): e0205756.
doi: 10.1371/journal.pone.0205756
|
[29] |
Ledsgaard L, Ljungars A, Rimbault C, et al. Advances in antibody phage display technology. Drug Discovery Today, 2022, 27(8): 2151-2169.
doi: 10.1016/j.drudis.2022.05.002
|
[30] |
Jaroszewicz W, Morcinek-Orłowska J, Pierzynowska K, et al. Phage display and other peptide display technologies. FEMS Microbiology Reviews, 2022, 46(2): fuab052.
doi: 10.1093/femsre/fuab052
|
[31] |
Muyldermans S. Applications of nanobodies. Annual Review of Animal Biosciences, 2021, 9: 401-421.
doi: 10.1146/annurev-animal-021419-083831
pmid: 33233943
|
[32] |
Weiss R A, Verrips C T. Nanobodies that neutralize HIV. Vaccines, 2019, 7(3): 77.
doi: 10.3390/vaccines7030077
|
[33] |
Omidfar K, Daneshpour M. Advances in phage display technology for drug discovery. Expert Opinion on Drug Discovery, 2015, 10(6): 651-669.
doi: 10.1517/17460441.2015.1037738
pmid: 25910798
|
[34] |
Doores K J, Fulton Z, Huber M, et al. Antibody 2G 12 recognizes di-mannose equivalently in domain- and nondomain-exchanged forms but only binds the HIV-1 glycan shield if domain exchanged. Journal of Virology, 2010, 84(20): 10690-10699.
doi: 10.1128/JVI.01110-10
pmid: 20702629
|
[35] |
Burton D R, Pyati J, Koduri R, et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science, 1994, 266(5187): 1024-1027.
pmid: 7973652
|
[36] |
Yang G, Holl T M, Liu Y, et al. Identification of autoantigens recognized by the 2F5 and 4E 10 broadly neutralizing HIV-1 antibodies. The Journal of Experimental Medicine, 2013, 210(2): 241-256.
doi: 10.1084/jem.20121977
|
[37] |
McCoy L E, Burton D R. Identification and specificity of broadly neutralizing antibodies against HIV. Immunological Reviews, 2017, 275(1): 11-20.
doi: 10.1111/imr.12484
pmid: 28133814
|
[38] |
Walker L M, Huber M, Doores K J, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature, 2011, 477(7365): 466-470.
doi: 10.1038/nature10373
|
[39] |
Walker L M, Phogat S K, Chan-Hui P Y, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science, 2009, 326(5950): 285-289.
doi: 10.1126/science.1178746
pmid: 19729618
|
[40] |
Doria-Rose N A, Bhiman J N, Roark R S, et al. New member of the V1V2-directed CAP256-VRC 26 lineage that shows increased breadth and exceptional potency. Journal of Virology, 2015, 90(1): 76-91.
doi: 10.1128/JVI.01791-15
|
[41] |
Bonsignori M, Hwang K K, Chen X, et al. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. Journal of Virology, 2011, 85(19): 9998-10009.
doi: 10.1128/JVI.05045-11
pmid: 21795340
|
[42] |
Bonsignori M, Zhou T Q, Sheng Z Z, et al. Maturation pathway from germline to broad HIV-1 neutralizer of a CD4-mimic antibody. Cell, 2016, 165(2): 449-463.
doi: 10.1016/j.cell.2016.02.022
pmid: 26949186
|
[43] |
Huang J H, Ofek G, Laub L, et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature, 2012, 491(7424): 406-412.
doi: 10.1038/nature11544
|
[44] |
Falkowska E, Le K, Ramos A, et al. Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp 41 on cleaved envelope trimers. Immunity, 2014, 40(5): 657-668.
doi: 10.1016/j.immuni.2014.04.009
pmid: 24768347
|
[45] |
Huang J H, Kang B H, Pancera M, et al. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature, 2014, 515(7525): 138-142.
doi: 10.1038/nature13601
|
[46] |
Perry S T, Keogh E, Morton M, et al. Single-cell screening method for the selection and recovery of antibodies with desired specificities from enriched human memory B cell populations. Journal of Visualized Experiments, 2019(150). DOI: 10.3791/59809.
doi: 10.3791/59809
|
[47] |
Starkie D O, Compson J E, Rapecki S, et al. Generation of recombinant monoclonal antibodies from immunised mice and rabbits via flow cytometry and sorting of antigen-specific IgG+ memory B cells. PLoS One, 2016, 11(3): e0152282.
doi: 10.1371/journal.pone.0152282
|
[48] |
Sok D, Pauthner M, Briney B, et al. A prominent site of antibody vulnerability on HIV envelope incorporates a motif associated with CCR5 binding and its camouflaging glycans. Immunity, 2016, 45(1): 31-45.
doi: 10.1016/j.immuni.2016.06.026
pmid: 27438765
|
[49] |
Mouquet H, Scharf L, Euler Z, et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109(47): E3268-E3277.
|
[50] |
Liao H X, Lynch R, Zhou T Q, et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature, 2013, 496(7446): 469-476.
doi: 10.1038/nature12053
|
[51] |
Zhou T Q, Georgiev I, Wu X L, et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science, 2010, 329(5993): 811-817.
doi: 10.1126/science.1192819
pmid: 20616231
|
[52] |
van Gils M J, van den Kerkhof T L G M, Ozorowski G, et al. An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability. Nature Microbiology, 2017, 2(2): 1-10.
|
[53] |
Wu X L, Zhou T Q, Zhu J, et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science, 2011, 333(6049): 1593-1602.
doi: 10.1126/science.1207532
pmid: 21835983
|
[54] |
Scheid J F, Mouquet H, Ueberheide B, et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science, 2011, 333(6049): 1633-1637.
doi: 10.1126/science.1207227
pmid: 21764753
|
[55] |
Carbonetti S, Oliver B G, Vigdorovich V, et al. A method for the isolation and characterization of functional murine monoclonal antibodies by single B cell cloning. Journal of Immunological Methods, 2017, 448: 66-73.
doi: S0022-1759(17)30067-4
pmid: 28554543
|
[56] |
Kreer C, Döring M, Lehnen N, et al. openPrimeR for multiplex amplification of highly diverse templates. Journal of Immunological Methods, 2020, 480: 112752.
doi: 10.1016/j.jim.2020.112752
|
[57] |
Gieselmann L, Kreer C, Ercanoglu M S, et al. Effective high-throughput isolation of fully human antibodies targeting infectious pathogens. Nature Protocols, 2021, 16(7): 3639-3671.
doi: 10.1038/s41596-021-00554-w
pmid: 34035500
|
[58] |
Akagi S, Nakajima C, Tanaka Y, et al. Flow cytometry-based method for rapid and high-throughput screening of hybridoma cells secreting monoclonal antibody. Journal of Bioscience and Bioengineering, 2018, 125(4): 464-469.
doi: S1389-1723(17)30577-7
pmid: 29174537
|
[59] |
Xu Z Y, Walker S, Wise M C, et al. Induction of tier-2 neutralizing antibodies in mice with a DNA-encoded HIV envelope native like trimer. Nature Communications, 2022, 13(1): 1-18.
doi: 10.1038/s41467-021-27699-2
|
[60] |
Setliff I, Shiakolas A R, Pilewski K A, et al. High-throughput mapping of B cell receptor sequences to antigen specificity. Cell, 2019, 179(7): 1636-1646.e15.
doi: S0092-8674(19)31224-3
pmid: 31787378
|
[61] |
Shiakolas A R, Kramer K J, Wrapp D, et al. Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. Cell Reports Medicine, 2021, 2(6): 100313.
doi: 10.1016/j.xcrm.2021.100313
|
[62] |
Kramer K J, Johnson N V, Shiakolas A R, et al. Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition. Cell Reports, 2021, 37(1): 109784.
doi: 10.1016/j.celrep.2021.109784
|
[63] |
Walker L M, Shiakolas A R, Venkat R, et al. High-throughput B cell epitope determination by next-generation sequencing. Frontiers in Immunology, 2022, 13: 855772.
doi: 10.3389/fimmu.2022.855772
|
[64] |
Hu T S, Chitnis N, Monos D, et al. Next-generation sequencing technologies: an overview. Human Immunology, 2021, 82(11): 801-811.
doi: 10.1016/j.humimm.2021.02.012
pmid: 33745759
|
[65] |
Sun C J, Zuo T, Wen Z Y. First clinical study of germline-targeting strategy: one step closer to a successful bnAb-based HIV vaccine. The Innovation, 2023, 4(1): 100374.
doi: 10.1016/j.xinn.2023.100374
|
[66] |
Burton D R. Advancing an HIV vaccine; advancing vaccinology. Nature Reviews Immunology, 2019, 19(2): 77-78.
doi: 10.1038/s41577-018-0103-6
pmid: 30560910
|
[67] |
Yan Q H, He P, Huang X H, et al. Germline IGHV3-53-encoded RBD-targeting neutralizing antibodies are commonly present in the antibody repertoires of COVID-19 patients. Emerging Microbes & Infections, 2021, 10(1): 1097-1111.
|
[68] |
Tan T J C, Yuan M, Kuzelka K, et al. Sequence signatures of two public antibody clonotypes that bind SARS-CoV-2 receptor binding domain. Nature Communications, 2021, 12(1): 1-10.
doi: 10.1038/s41467-020-20314-w
|
[69] |
Setliff I, McDonnell W J, Raju N, et al. Multi-donor longitudinal antibody repertoire sequencing reveals the existence of public antibody clonotypes in HIV-1 infection. Cell Host & Microbe, 2018, 23(6): 845-854.e6.
|
[70] |
Parola C, Neumeier D, Reddy S T. Integrating high-throughput screening and sequencing for monoclonal antibody discovery and engineering. Immunology, 2018, 153(1): 31-41.
doi: 10.1111/imm.12838
pmid: 28898398
|
[71] |
Sun Z H, Yan L X, Tang J S, et al. Brief introduction of current technologies in isolation of broadly neutralizing HIV-1 antibodies. Virus Research, 2018, 243: 75-82.
doi: S0168-1702(17)30572-5
pmid: 29051051
|
[72] |
Huang J H, Kang B, Ishida E, et al. Identification of a CD4-binding-site antibody to HIV that evolved near-pan neutralization breadth. Immunity, 2016, 45(5): 1108-1121.
doi: S1074-7613(16)30438-1
pmid: 27851912
|
[73] |
Sajadi M M, Dashti A, Rikhtegaran Tehrani Z, et al. Identification of near-pan-neutralizing antibodies against HIV-1 by deconvolution of plasma humoral responses. Cell, 2018, 173(7): 1783-1795.e14.
doi: S0092-8674(18)30393-3
pmid: 29731169
|
[74] |
Rudicell R S, Do Kwon Y, Ko S Y, et al. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. Journal of Virology, 2014, 88(21): 12669-12682.
doi: 10.1128/JVI.02213-14
pmid: 25142607
|
[75] |
Zhou T Q, Lynch R, Chen L, et al. Structural repertoire of HIV-1-neutralizing antibodies targeting the CD 4 supersite in 14 donors. Cell, 2015, 161(6): 1280-1292.
doi: 10.1016/j.cell.2015.05.007
|
[76] |
Williams L D, Ofek G, Schätzle S, et al. Potent and broad HIV-neutralizing antibodies in memory B cells and plasma. Science Immunology, 2017, 2(7): eaal2200.
|
[77] |
Schoofs T, Barnes C O, Suh-Toma N, et al. Broad and potent neutralizing antibodies recognize the silent face of the HIV envelope. Immunity, 2019, 50(6): 1513-1529.e9.
doi: S1074-7613(19)30194-3
pmid: 31126879
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|